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In April this year, a new influenza virus of swine origin emerged in Mexico and spread rapidly 
around the world. As the Northern hemisphere winter flu season kicks off, Laura Vargas-Parada 
reports on the measures that Mexico is taking to combat the H1N1 pandemic.Although Mexico has been actively 
engaged in establishing a health emer-
gency response network for a decade, 
the emergence of the pandemic (H1N1) 
2009 flu virus this Spring put the network 
under intense pressure and prompted 
evaluation of omissions and unexpected 
outcomes. One major flaw in the Pre-
paredness and Response Plan was 
that “all possible scenarios considered 
that the potential risk would arrive from 
abroad, most likely from Asia, giving us 
time to react to the emergency. We never 
expected the epidemic to start here,” 
explains Mexico’s health minister José 
Angel Córdova. “In a matter of hours 
important decisions had to be taken with 
the scarce information we had at hand,” 
he adds. Ignacio Villaseñor, undersec-
retary of health for Mexico City’s local 
government, emphasizes that “at that 
moment, what we needed to achieve was 
that those that were healthy not to get 
sick, those that were sick not to develop 
severe disease, and those who devel-
oped severe disease not to die.” Strict 
measures to prevent the spread of the 
H1N1 virus were implemented. “This was 
a new virus; no one knew how virulent it 
was or its capacity for transmission so we 
were extremely cautious. Putting it into 
perspective, now we know the disease 
is not as severe as it was expected…but 
not at that time,” says Córdova. Mexico 
was the only country during the emer-
gence of the H1N1 pandemic to estab-
lish a broad-based strategy for school 
closures and bans on public gatherings; 
in Mexico City, the world’s third largest 
metropolis, all nonessential activities 
were shut down. It is estimated that the 
pandemic cost Mexico ~$4 billion dollars 
(0.4% of its GDP).
One of the major questions raised dur-
ing the Spring pandemic was the death 
toll observed in Mexico and not else-
where. “A retrospective analysis of the 
epidemiological data has shown that one main contributing factor for the death of 
patients was the delayed admission and 
delayed initiation of antiviral treatment,” 
explains Córdova. In Mexico, most peo-
ple who get the flu never go to a doctor. 
Even worse, it is common for people to 
self-diagnose and to treat themselves 
with homemade remedies or, as few 
drugs require a prescription, they sim-
ply buy them at the drugstore. “With a 
massive media campaign, people are 
now looking for medical attention at the 
onset of symptoms and the death rate 
has diminished to be currently similar to 
what is reported globally. Before April 
23 people took up to nine days to see a 
doctor, now the average is a day and a 
half,” says Córdova.
As of December 2 this year, there have 
been 66,070 confirmed cases of pan-
demic H1N1 (2009) flu and 671 deaths 
in Mexico (for comparison, according 
to the National System on Health Infor-
mation, there were 14,575 deaths from 
acute respiratory infections in 2007). 
Much has been learned from the early 
days of the H1N1 (2009) pandemic and 
many changes have been implemented 
in time for this winter’s flu season.
Lessons Learned
Vaccines
So far this year, the Mexican govern-
ment has invested ?$330 million to 
buy general supplies, antivirals, vac-
cines, laboratory equipment, mechani-
cal ventilators, and monitors for acute 
care. The purchase of H1N1 2009 vac-
cine alone is expected to cost ?$200 
million. In the US, 250 million doses of 
swine flu vaccine have been ordered at 
a cost of $1.5 billion and the US Con-
gress has set aside $7.65 billion to fight 
pandemic flu. According to the US Cen-
ters for Disease Control and Prevention 
(CDC), as of December 4 there were 73 
million doses of H1N1 vaccine avail-
able in the US. Like many other coun-Cell 139, Detries, Mexico has been struggling to 
obtain a sufficient supply of H1N1 flu 
vaccine. A recent agreement with the 
French pharma company Sanofi-Aventis 
enabled Mexico to obtain 865,000 doses 
of Panenza vaccine last month (215,000 
doses from France and 650,000 doses 
from the US). The next batch “will arrive 
between December and March to com-
plete a total of 30 million,” says Ale-
jandro Macías, special commissioner 
of the Federal Government for human 
influenza and assistant director at the 
National Institute of Medical Sciences 
and Nutrition. Sanofi-Aventis is supply-
ing 20 million doses, and GlaxoSmith-
Kline (GSK) is providing an additional 10 
million doses of its H1N1 pandemic vac-
cine with adjuvant (Arepanrix) manufac-
tured in Canada. “As the number of vac-
cines is limited, there will be a program 
to prioritize health-care workers, preg-
nant women, children from six months 
to three years old, as well as individuals 
at risk of severe disease, such as people 
with chronic underlying illnesses,” says 
Macías. As for seasonal influenza vacci-
nation, since October 5, 20 million doses 
have been given to health-care workers, 
children, the elderly, and those over 50 
with conditions like asthma, diabetes, 
or obesity. “We expect to complete sea-
sonal vaccination by December,” adds 
Macías. Seasonal influenza vaccination 
was introduced in Mexico as part of the 
annual national vaccination campaign 
in 2004. To assure the efficient alloca-
tion of both vaccines and antivirals, “we 
have implemented a central logistics 
and delivery system,” explains Córdova. 
Both vaccines and antivirals are being 
distributed by Biologicals and Reactives 
of Mexico (BIRMEX), “which has a very 
well established network,” says Macías. 
(BIRMEX is a state-owned company 
that produces, distributes, and imports 
vaccines, heterologous sera, and clini-
cal diagnostic products).cember 24, 2009 ©2009 Elsevier Inc. 1203
Many have complained that the short-
age of H1N1 flu vaccine is a result of 
the monopoly imposed by the countries 
where the vaccine is produced. “For 
decades, Mexico produced all the vac-
cines that were applied in the country. 
However, very bad political decisions 
reduced our capability to mainly com-
mercialize and distribute the vaccines 
and products others produce,” explains 
infectious diseases expert Samuel Ponce 
de León, a former medical director for 
Bristol-Myers Squibb in Mexico and cur-
rent director of BIRMEX. “At the end of 
2007, BIRMEX acquired a production 
plant with the aim of regaining capabil-
ity to produce vaccines and established 
an agreement with Sanofi-Aventis for 
the technological transfer and construc-
tion of a plant for producing seasonal 
influenza vaccine.” With an investment 
of $250 million, the plant, located in the 
State of Mexico, will initiate security and 
stability tests in 2011 and is expected to 
start producing around 25 million doses 
of vaccine by 2012. Ponce de León adds, 
“it has been a great mistake not to have 
given priority to investment in the devel-
opment of science and technology” as it 
is clearly becoming a matter of national 
security.
Public Health
The winter flu season in Mexico is 
expected to peak next month, and an 
agreement has been reached that public 
health hospitals will reserve at least 12% 
of their beds for pandemic flu patients. 
“To expand hospital capacity, parking 
lots and classrooms will be equipped 
to receive the patients, non-essential 
activities like elective surgeries will be 
suspended, and those patients that can 
be taken care of at home will be dis-
charged,” says Córdova. In Mexico City, 
the local government has designated two 
separate hospitals for the management 
of adults and children with pandemic flu. 
The remaining 26 local hospitals and 220 
outpatient clinics will remain open during 
evenings and weekends to assist people 
seeking medical attention.
As people are being advised to con-
sult a physician at the first signs of flu 
symptoms like fever and cough, triage 
will be important for distributing scarce 
resources in a rational manner. “We have 
found that … caravanas de la salud are 
very useful,” says Córdova. Launched in 1204 Cell 139, December 24, 2009 ©2009 El2007, caravanas de la salud is a nation-
wide system of mobile healthcare (medi-
cal and dental) clinics operated by phy-
sicians and nurses that provide regular 
primary care to low-income individuals 
living in remote areas throughout the 
country. “During the early outbreak they 
gave thousands of medical consults, 
resolving many of the enquiries and 
reducing the number of people visiting 
the hospitals,” says Córdova.
A key measure to counter the flu sea-
son this winter is a health promotion and 
prevention program. “We need to cre-
ate a culture of prevention,” says Esther 
Orozco, general director of the Institute 
of Science and Technology of Mexico 
City. Córdova notes that “a major strat-
egy in our program for the winter sea-
son is the training of personnel. Differ-
ent workshops have been put in place 
at three major levels: physicians and 
nurses (to standardize diagnosis and 
treatment), hospital staff members (to 
respond to the need for adequate hospi-
tal infrastructure), and state health minis-
ters.” Guides, educational material, and 
handbooks used in the workshops as 
well as information for the general public 
are available online (http://www.promo-
cion.salud.gob.mx/dgps/interior1/influ-
enza_estacional.html).
Despite all of these efforts, Mexico still 
lags behind other countries in investing in 
public health. In 2007, for example, Mex-
ico invested 5.9% of its GDP on health, 
compared with an average of 9.1% for 
members of OECD (Organisation for Eco-
nomic Cooperation and Development) 
and 16% for the US (http://stats.oecd.
org/Index.aspx?datasetcode=SNA_
TABLE1). The public health expenditure 
per capita for the same year was $372 in 
Mexico compared with $3310 in the US.
Diagnostics
A major problem with the H1N1 pan-
demic flu outbreak in April was meeting 
the demand for rapid diagnosis. At that 
time, only the Institute of Epidemiologi-
cal Diagnosis and Reference (InDRE) in 
Mexico City (Mexico’s National Pub-
lic Health Laboratory) had the facilities 
to implement the CDC’s protocol for 
using RT-PCR to detect the influenza A 
(H1N1) 2009 virus strain. Major invest-
ments were made after the outbreak to 
upgrade Mexico’s diagnostic laboratory 
network. Currently, 27 state public health sevier Inc.laboratories (out of 31), 1 laboratory in 
the Mexican Institute for Social Security 
network, and 3 (out of 12) of the National 
Institutes of Health in Mexico City are 
now equipped to use RT-PCR to detect 
the H1N1 virus. This month, Mexico City 
expects to open its own fully equipped 
state public health laboratory at the Uni-
versity of Mexico City.
For seasonal influenza, “28 state labo-
ratories have the capability to determine 
if the samples sent by sentinel surveil-
lance clinics are influenza A or B by 
means of immunofluorescence assays,” 
says InDRE deputy director Celia Alpu-
che-Aranda. “All positive samples for 
influenza, and 10% of the negative ones 
are then sent for confirmation to InDRE. 
If positivity is confirmed then subtyp-
ing (H1, H3, and H5) is done and a viral 
isolate obtained. For subtyping, we use 
the hemagglutination-inhibition test and 
RT-PCR. Samples are sent to CDC, our 
collaborative center in the Flu-Net net-
work,” she says. “Surveillance for [pan-
demic (H1N1) virus] mutations is done 
by sequencing the neuraminidase gene. 
Up to now, 106 different clinical speci-
mens collected from different dates and 
locations have been analyzed and all 
have been shown to be susceptible to 
neuraminidase inhibitors,” adds Alpu-
che-Aranda. “Selected virus isolates 
mainly from severe hospitalized cases 
and deaths will be fully sequenced using 
CDC’s overlapping forward and reverse 
primers. At this moment we are stan-
dardizing the technique,” she says.
Science and Policy
With most of the laboratory work focus-
ing on diagnosis, there has been little 
time for monitoring emerging mutations 
and viral reassortants. One way to solve 
this limitation “would be to bring in aca-
demic labs outside of the government 
testing system, but sharing of clinical 
materials and trust is low,” says Susana 
López Charretón, a virologist from the 
Institute of Biotechnology at the National 
University of Mexico (UNAM). “We can 
provide state-of-the art technology and 
human resources to help them [but] there 
was no response, no sign of interest. We 
could have collaborated in the analysis 
of a national seroepidemiology survey 
to know how many people have been 
already exposed to the virus,” she says. 
Another problem that surfaced with the 
outbreak was the lack of trained person-
nel to respond to an emergency of this 
type. “We are still a very small scientific 
community and are in desperate need of 
more virologists” says López Charretón.
The perception of a lack of collabora-
tion between clinical and other research-
ers, and between government laborato-
ries and academia across the country, is 
a major concern. “During this epidemic, 
policy makers failed to recognize what 
public universities had to offer: the power 
of a well-established scientific commu-
nity that was ready to help in harnessing 
the best available knowledge to solve 
the country’s problems,” says Antonio 
Lazcano, an evolutionary biologist at 
UNAM. “We were severely criticized for 
sending samples of the suspected cases 
to the Public Health Agency of Canada 
and the US Centers for Disease Control 
and Prevention,” says Alpuche-Aranda. 
“In Mexico, we have first level research 
groups, but none of them had experi-
ence, neither the primers nor the probes, 
to isolate unknown pathogens. We were 
in a rush to sort out what was going on. 
Besides, the World Health Organization 
requires a set of standards to safely han-
dle and work with new pathogens,” she explains. Fátima Fernández Christlieb, a 
sociologist at UNAM, points out that “the 
new influenza virus highlighted a large list 
of shortages, among them, the lack of 
coordination within the academic com-
munity and the absence of links between 
academia and those who make the deci-
sions that affect the country.” Córdova 
concedes: “We worked together. Still, 
we need to work out a better strategy for 
collaborating with academia.”
Another issue of concern is that 
although Mexican researchers com-
piled valuable information during the 
initial H1N1 influenza outbreak, very 
few articles have been published in 
peer-reviewed journals. Villaseñor 
explains, “[at that time] we were over-
loaded with surveillance and field work 
and did not have enough staff.” A team 
led by Lazcano chose to publish a pre-
liminary evolutionary analysis of the 
virus on their own blog page “with the 
goal of reaching a much broader audi-
ence,” Lazcano explains. For Gustavo 
Cruz Pacheco, at UNAM’s Institute of 
Applied Mathematics, who studied the 
dynamics of the outbreak when control 
measures were implemented, the diffi-
culty was to cross disciplines and pub-
lish in biology journals.Cell 139, DeAs the winter flu season proceeds, 
Mexico continues to look for ways to 
bolster public health programs and to 
make better use of its scientists and 
research facilities. As Córdova points 
out, “there will always be problems. 
And the best way to face them is not by 
hiding them, but to bring them forward, 
ask for all the support needed, and 
make all decisions based upon the best 
available scientific data.” Carlos Arias, 
director of the Biotechnology Institute 
at UNAM, concurs: “The only way to 
make decisions and establish public 
policies is through the knowledge and 
evidence that comes from scientific 
research.” From the point of view of 
policy implementation, Orozco says, 
“most Mexican politicians are scientifi-
cally illiterate and do not have a vision 
about the importance of science. That 
is why, although we can say we have 
science, that won’t be enough while 
decision-makers do not recognize the 
power of scientific research in making 
policies on the basis of evidence. As a 
country we need to know why we want 
science, which are the plans, the proj-
ects, the route, the aims that we want 
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